Rheumatoid arthritis subgroup with type i interferon signature: Comment on the article by Thurlings et al

Arthritis and Rheumatism

Volumn 63, Issue 12, 2011, Pages 4033-

  Park, Jin Kyun ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; COLONY STIMULATING FACTOR 1; INFLIXIMAB; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

BONE DEVELOPMENT; CYTOKINE PRODUCTION; DISEASE COURSE; GENE EXPRESSION; HUMAN; LETTER; OSTEOCLAST; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INTERFERON TYPE I; MALE;

EID: 82455210464     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30609     Document Type: Letter

References (8)

1. Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010; 62: 3607-14.
2. Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-α monoclonal antibody, infliximab. Rheumatology (Oxford) 2008; 47: 780-8. (Pubitemid 351796361)
3. Boyle WJ, Simonet WS, Lacey DL,. Osteoclast differentiation and activation. Nature 2003; 423: 337-42. (Pubitemid 40852708)
4. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 2000; 408: 600-5.
5. Mensah KA, Mathian A, Ma L, Xing L, Ritchlin CT, Schwarz EM,. Mediation of nonerosive arthritis in a mouse model of lupus by interferon-α- stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. Arthritis Rheum 2010; 62: 1127-37.
6. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK,. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-503. (Pubitemid 40663941)
7. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
8. Lafyatis R, York M, Marshak-Rothstein A,. Antimalarial agents: closing the gate on Toll-like receptors? [editorial]. Arthritis Rheum 2006; 54: 3068-70. (Pubitemid 44622073)